We are live on ! Find out more
NYMX

Nymox Pharmaceutical Corp
NYMX

Delisted

NYMX was delisted on the 6th of July, 2023.

Back to rankings

3 hedge funds and large institutions have $48K invested in Nymox Pharmaceutical Corp in 2024 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

81% more capital invested

Capital invested by funds: $26.6K → $48K (+$21.4K)

50% more funds holding

Funds holding: 2 → 3 (+1)

Holders
3
Holders Change
+1
Holders Change %
+50%
% of All Funds
0.04%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
DDC
DF Dent & Co
Maryland
+$30K

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
DDC
1
DF Dent & Co
Maryland
$30K +$30K +75,000 New
FCFC
2
First Citizens Financial Corp
Iowa
$14K – – –
CAM
3
Cubic Asset Management
Massachusetts
$4K – – –

NYMX Hedge Fund Activity: Q1 2024 in Review

3 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Nymox Pharmaceutical Corp (NYMX) for Q1 2024, worth a combined $48K — up 81% from $26.6K a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new NYMX positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.

The largest buyer was DF Dent & Co, opening a new position worth an estimated $30K.

  • 3 institutional investors held Nymox Pharmaceutical Corp (NYMX) as of Q1 2024, up from 2 in Q4 2023.
  • Funds reported $48K of Nymox Pharmaceutical Corp stock for Q1 2024, up 81% quarter-over-quarter.
  • 1 fund opened new Nymox Pharmaceutical Corp positions in Q1 2024 and 0 closed out, a net change of +1 holder.
  • The largest Nymox Pharmaceutical Corp buyer in Q1 2024 was DF Dent & Co, an estimated $30K added.

Based on aggregated 13F filings for Q1 2024.